Real-Time Nucleic Acid Sequence-Based Amplification to Predict the Clinical Outcome of Invasive Aspergillosis

다국어 초록 (Multilingual Abstract)

Monitoring the response to therapy for invasive aspergillosis (IA) is essential for the management of patients with hematologic diseases. We evaluated the correlation between the outcome of real-time nucleic acid sequence-based amplification (RTi-NASBA) for Aspergillus 18S rRNA and the clinical outcome of IA. A total of 157 serum samples from 29 patients with IA were tested for RTi-NASBA. The treatment response and mortality were compared with the NASBA outcome (whether the NASBA value was converted to negative or not) at 12 weeks after the start of antifungal therapy. At 12 weeks, there was a moderate correlation between the treatment failure and persistently positive NASBA (κ = 0.482; P = 0.019). Deaths attributable to IA were more prevalent in patients without negative conversion of NASBA than in those with negative conversion (50% vs 5%;P = 0.013). Significant factors of treatment failure at 12 weeks were the status of hematologic disease (nonremission; P = 0.041) and the NASBA outcome (failure of negative conversion; P = 0.024). Survival was significantly better in patients with negative conversion of NASBA than those with persistently positive values (P = 0.036). This study suggests that the serial monitoring of RTi-NASBA could be useful for prediction of the clinical outcome in hematologic patients with IA.

참고문헌 (Reference)

1 유진홍, "침습성 국균증의 진단과 경과 관찰을 위한 NASBA의 평가 : 예비보고" 대한감염학회 35 (35): 99-106, 2003

2 김시현, "Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients" WILEY-BLACKWELL 54 (54): 523-530, 201111

3 Woods G, "Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer" 110 : 830-834, 2007

4 Koo S, "Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis" 48 : 1255-1260, 2010

5 Bretagne S, "Primary diagnostic approaches of invasive aspergillosis: molecular testing" 49 : 48-53, 2011

6 Slobbe L, "Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study" 47 : 1507-1512, 2008

7 Perlin DS, "Molecular diagnostic platforms for detecting Aspergillus" 47 : 223-232, 2009

8 Brodoefel H, "Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis: kinetics of CT morphology and correlation with clinical findings and outcome" 187 : 404-413, 2006

9 Chmura Kraemer H, "Kappa coefficients in medical research" 21 : 2109-2129, 2002

10 Maschmeyer G, "Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients" 67 : 1567-1601, 2007

11 이종욱, "Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea" Nature Publishing Group 34 (34): 497-504, 200409

12 Caillot D, "Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia" 19 : 253-259, 2001

13 Patterson SS, "Increased precision of microbial RNA quantification using NASBA with an internal control" 60 : 343-352, 2005

14 Maertens J, "Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients" 115 : 355-362, 2009

15 김시현, "Evaluation of nucleic acid sequence based amplification using fluorescence resonance energy transfer (FRET-NASBA) in quantitative detection of Aspergillus 18S rRNA" INFORMA HEALTHCARE 49 (49): 73-79, 201101

16 De Pauw B, "European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ MSG) Consensus Group" 46 : 1813-1821, 2008

17 White PL, "European Aspergillus PCR Initiative. Aspergillus PCR: one step closer to standardization" 48 : 1231-1240, 2010

18 Marr KA, "Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients" 34 : 909-917, 2002

19 Wheat LJ, "Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay" 27 : 245-251, 2008

20 Cordonnier C, "Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria" 47 : 674-683, 2008

21 이혜련, "Construction of internal control for the quantitative assay of Aspergillus fumigatus using real-time nucleic acid sequence-based amplification" ELSEVIER SCIENCE INC 60 : 121-124, 200801

22 Jin-Hong Yoo, "Comparison of the Real-time Nucleic Acid Sequence-basedAmplification (RTi-NASBA) with Conventional NASBA, andGalactomannan Assay for the Diagnosis of Invasive Aspergillosis" 대한의학회 22 (22): 672-676, 2007

23 Wiederhold NP, "Assessment of serum (1->3)- beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis" 52 : 1176-1178, 2008

24 Vallor AC, "Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture" 52 : 2593-2598, 2008

25 Latgé JP, "Aspergillus fumigatus and aspergillosis" 12 : 310-350, 1999

26 Hummel M, "Aspergillus PCR testing: results from a prospective PCR study within the AmBiLoad trial" 85 : 164-169, 2010

27 Segal BH, "Aspergillosis" 360 : 1870-1884, 2009

28 Yoo JH, "Application of nucleic acid sequence-based amplification for diagnosis of and monitoring the clinical course of invasive aspergillosis in patients with hematologic diseases" 40 : 392-398, 2005

29 Marr KA, "Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay" 40 : 1762-1769, 2005

30 Hughes WT, "2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer" 34 : 730-751, 2002